Open AccessPharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211)
Author(s) -
Keith W. Crawford,
Chonghua Li,
Anther Keung,
Zhaohui Su,
Michael D. Hughes,
Wayne Greaves,
Daniel R. Kuritzkes,
Roy M. Gulick,
Charles Flexner
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181c9caac
Subject(s) - ccr5 receptor antagonist , human immunodeficiency virus (hiv) , protocol (science) , pharmacodynamics , medicine , pharmacokinetics , antiretroviral therapy , pharmacology , psychology , viral load , virology , alternative medicine , receptor , pathology , chemokine , chemokine receptor
This substudy of AIDS Clinical Trials Group (ACTG) Protocol 5211 explored the relationship between antiretroviral effect and plasma concentrations of vicriviroc, an investigational CCR5 antagonist for HIV infection.